Search results
'An Officer and a Gentleman' actor Louis Gossett Jr. died from COPD, report says: What to know about...
Yahoo Canada Style· 7 hours agoThis article is for informational purposes only and is not a substitute for professional medical...
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 5 hours agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 4 days agoKey opinion leaders (KOLs) interviewed by GlobalData have expressed mixed opinions about Fasenra,...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 7 hours agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Earnings call: Pulmonx sees 30% sales boost in Q1, eyes $84M annual target By Investing.com
Investing.com· 17 hours agoPulmonx Corporation (ticker: LUNG) reported a robust start to 2024 with a 30% increase in worldwide...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
WFRV 5 Green Bay· 2 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 21 hours agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Q1 2024 Pulmonx Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 16 hours agoAs I look ahead, I'm excited to leverage the expertise of our entire team whose collective experience in interventional pulmonology and dedication to our mission to deliver on our commitments ...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 16 hours ago(Regeneron shares the rights to...injections per year without sacrificing efficacy, an obvious...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 17 hours agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...